VCM
AGIO icon

Voleon Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Voleon Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,679
Closed -$327K – 768
2026
Q1 		$327K Buy
+9,679
New +$274K 0.01% 657
2025
Q4 		– Sell
-6,682
Closed -$268K – 781
2025
Q3 		$268K Buy
+6,682
New +$251K 0.01% 755

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Voleon Capital Management's AGIO Position: Q2 2026 in Review

Voleon Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 9,679 shares — an estimated $327K sold.

Voleon Capital Management first reported a position in AGIO in Q3 2025 and held it in 2 quarters. The position peaked at $327K in Q1 2026. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Voleon Capital Management reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Voleon Capital Management sold 9,679 Agios Pharmaceuticals shares in Q2 2026, an estimated $327K.
  • Voleon Capital Management first reported a position in Agios Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Voleon Capital Management's Agios Pharmaceuticals position peaked at $327K in Q1 2026.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.